I treat patients who fulfill the eligibility criteria of CheckMate 274. Thus, patients must have had radical surgery (R0, with negative surgical margins) within 120 days before randomization, with or without neoadjuvant cisplatin-based chemotherapy. Patients must have had pathological evidence of ur...

I would discuss the use of adjuvant nivolumab in the patient population with high risk MIBC that were included in the CM274 study. The improvement in DFS was seen in the ITT population (HR 0.70) and the PD-L1 + population (HR 0.55). Although the DFS is more pronounced in the PD-L1+ group, I do not t...

At present, we are still functioning without the information we need for risk-adapted decision-making about adjuvant Nivolumab. Patients with high volume residual disease, particularly nodal disease, following neoadjuvant chemotherapy are at high risk for recurrence, metastasis, and death from bladd...

Adjuvant nivolumab should be considered for patients with urothelial cancer at high risk for recurrence after curative intent surgery which, as per the eligibility for CM274, included patients with >/= pT3 and/or pN+ who are cisplatin ineligible or decline adjuvant cisplatin-based chemotherapy or...